Extremely high-risk patients with acute coronary syndrome: How "extreme" should lipid-lowering therapy be if the LDL-C target <40 mg/dl is considered?

被引：5

作者：

Rallidis, Loukianos S. ^{[1
]}

Tsamoulis, Donatos ^{[2
]}

Leventis, Ioannis ^{[3
]}

Kalogeras, Petros ^{[4
]}

Delakis, Iosif ^{[5
]}

Samiotis, Elefterios ^{[1
]}

Kalantzis, Charalampos ^{[6
]}

Malkots, Belkis ^{[7
]}

Tasoulas, Dimitrios ^{[8
]}

Bouratzis, Vasileios ^{[4
]}

Eleutheriou, Dimitris ^{[9
]}

Dalos, Styliano ^{[10
]}

Potoupni, Victoria ^{[11
]}

Zervakis, Stelio ^{[12
]}

Xygka, Georgia ^{[13
]}

Miliotou, Argyro ^{[14
]}

Papathanasiou, Konstantinos A. ^{[1
,15
]}

Vlachopoulos, Charalambos ^{[6
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Univ Gen Hosp ATTIKON, Med Sch, Dept Cardiol 2, Athens, Greece

[2] Thriasio Gen Hosp, Dept Cardiol, Elefsina, Greece

[3] Univ Gen Hosp Larissa, Dept Cardiol, Larisa, Greece

[4] Univ Hosp Ioannina, Dept Cardiol 2, Ioannina, Greece

[5] Gen Hosp Nikea, Dept Cardiol 1, Piraeus, Greece

[6] Natl & Kapodistrian Univ Athens, Hippokrat Hosp, Med Sch, Dept Cardiol 1, Athens, Greece

[7] Democritus Univ Thrace, Med Sch, Dept Cardiol, Dragana, Alexandroupolis, Greece

[8] Gen Hosp Nikea, Dept Cardiol 2, Piraeus, Greece

[9] Gen Hosp Athens Evangelismos, Dept Cardiol 2, Athens, Greece

[10] Univ Gen Hosp Thessaloniki, Dept Cardiol 1, AHEPA, Thessaloniki, Greece

[11] Aristotle Univ Thessaloniki, Hippokrat Univ Hosp, Dept Cardiol 3, Thessaloniki, Greece

[12] Heraklion Univ Hosp, Dept Cardiol, Iraklion, Greece

[13] Patras Univ Hosp, Dept Cardiol, Patras, Greece

[14] Univ Athens, Alexandra Hosp, Dept Clin Therapeut, Athens, Greece

[15] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Med Sch, Dept Cardiol 2, Athens 12462, Greece

来源：

KARDIOLOGIA POLSKA | 2023年 / 81卷 / 10期

关键词：

D O I：

10.33963/KP.a2023.0147

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1012 / 1014

页数：3

共 48 条

[41] Targeting high-sensitivity C-reactive protein levels in acute coronary syndrome patients undergoing contemporary lipid-lowering therapy: a sub-analysis of the HIJ-PROPER trial
Kawada-Watanabe, Erisa
Yamaguchi, Junichi
Sekiguchi, Haruki
Arashi, Hiroyuki
Ogawa, Hiroshi
Hagiwara, Nobuhisa
JOURNAL OF CARDIOLOGY, 2020, 75 (05) : 500 - 506
[42] IMPACT OF HIGH SENSITIVITY C REACTIVE PROTEIN LEVELON CLINICAL OUTCOMES OF ACUTE CORONARY SYNDROME PATIENTS WITH DYSLIPIDEMIA UNDERGOING CONTEMPORARY LIPID LOWERING THERAPY
Watanabe, Erisa
Ogawa, Risa
Yamaguchi, Junichi
Sekiguchi, Haruki
Ogiso, Masataka
Arashi, Hiroyuki
Ogawa, Hiroshi
Hagiwara, Nobuhisa
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 53 - 53
[43] Is it enough to bring our patients with previous acute coronary syndrome to <55 LDL cholesterol values mg/dl? How the concept of "residual risk" can become a clinical opportunity for the patient at very high cardiovascular risk
Werren, Marika
Di Chiara, Antonio
Pavan, Daniela
Di Lenarda, Andrea
GIORNALE ITALIANO DI CARDIOLOGIA, 2020, 21 (08) : 599 - 601
[44] Predictive Value of Baseline High-Sensitivity C-Reactive Protein Level and Renal Function for Patients With Acute Coronary Syndrome Undergoing Aggressive Lipid-Lowering Therapy: A Subanalysis of HIJ-PROPER
Kawada-Watanabe, Erisa
Yamaguchi, Junichi
Kanbayashi, Keigo
Sekiguchi, Haruki
Arashi, Hiroyuki
Ogawa, Hiroshi
Hagiwara, Nobuhisa
AMERICAN JOURNAL OF CARDIOLOGY, 2018, 122 (11): : 1817 - 1823
[45] Low-density lipoprotein cholesterol levels and lipid-lowering treatment status among young and middle-aged ultra-high-risk patients with acute coronary syndrome in China
刘军
ChinaMedicalAbstracts(InternalMedicine), 2023, 40 (01) : 36 - 37
[46] THE IMPACT OF DECREASED HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL LEVEL AFTER LIPID-LOWERING THERAPY ON THE CLINICAL OUTCOMES IN PATIENTS WITH ACUTE CORONARY SYNDROME AND DYSLIPIDEMIA: A SUBANALYSIS OF THE HIJ-PROPER STUDY
Sekiguchi, Haruki
Matsui, Yuko
Kawada-Watanabe, Erisa
Yamaguchi, Junichi
Arashi, Hiroyuki
Ogawa, Hiroshi
Hagiwara, Nobuhisa
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 1758 - 1758
[47] Effectiveness and tolerability of ezetimibe 10 mg/d coadministered with statins vs statin dose-doubling in patients at high coronary artery disease risk who are not at target LDL-C on statin monotherapy:: The EZE (STAT)2 trial
Pandey, A. S.
Bissonnette, Stephane
Boukas, Stella
Sampalis, John S.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (06) : E132 - E132
[48] The impact of high-sensitive C-reactive protein value and renal function on clinical outcomes in patients with acute coronary syndrome under aggressive lipid lowering therapy: a sub-analysis of HIJ PR
Kawada-Watanabe, E.
Yamaguchi, J.
Arashi, H.
Sekiguchi, H.
Kanbayashi, K.
Fujii, S.
Ogawa, H.
Hagiwara, N.
EUROPEAN HEART JOURNAL, 2017, 38 : 127 - 128

← 1 2 3 4 5 →